Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS35699
- Development stage
- Preclinical
- Lead developer
- Akeso
- Modality
- Small Molecules
01
Overview
CS35699 is a small molecule inhibitor of cyclin-dependent kinase 2 (CDK2) being developed by Chipscreen Biosciences for the treatment of solid tumors. CDK2 plays a critical role in the regulation of the eukaryotic cell cycle, particularly during the G1 to S phase transition and throughout the S phase. Overexpression or hyperactivity of CDK2 is associated with uncontrolled cell proliferation in various cancers and has been identified as a potential resistance mechanism to CDK4/6 inhibitors. CS35699 is currently in the IND-enabling stage of development, aimed at providing a targeted therapeutic option for patients with tumors driven by CDK2 dysregulation.
02
Targets
CDK2 (Cyclin-dependent kinase 2)
Beyond the preview
Go deeper on CS35699.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS35699.